The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant Acinetobacter baumannii: a matched case-control study in intensive care units.
Huei-Ting Tsai; Jann-Tay Wang; Chien-Jen Chen; Shan-Chwen Chang (Profiled Author: Chi Chiung Grace Chen)
Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei 100, Taiwan.
Diagnostic microbiology and infectious disease 2008;62(3):298-305.
Nosocomial spreading of extensive drug-resistant Acinetobacter baumannii (EDRAB) is an emerging problem. To clarify the association between prior antibiotic usage and subsequent EDRAB acquisition, we conducted a one-to-one matched case-control study among patients in all intensive care units (ICUs) at the National Taiwan University Hospital, Taipei, Taiwan, during a 1-year period. A total of 113 pairs of patients were identified. We measured prior antibiotics exposure in 4 perspectives: usage, overall treatment duration, accumulated dosage, and treatment potency. We found positive associations between EDRAB acquisition and prior usage of imipenem and meropenem across 4 measures, especially in usage and average treatment potency (usage, odds ratio [OR](imipenem) = 3.7 with 95% confidence interval [CI] = 1.2-11.0, OR(meropenem) = 5.4 with 95% CI = 1.2-20.0; average treatment potency, OR(imipenem) = 5.3 with 95% CI = 1.3-22.0, OR(meropenem) = 3.4 with 95% CI = 1.0-12.0). Ceftazidime use with stronger treatment potency was also strongly associated with subsequent nosocomial EDRAB acquisition (OR = 5.5, 95% CI = 1.5-21.0). The OR of EDRAB acquisition greatly increased in patients who had previously been exposed to any 1 (OR = 5.5, 95% CI = 2.3-13.2) or to any 2 or 3 (OR = 11.1, 95% CI = 2.7-46.4) of the abovementioned antibiotics. Based on these findings, we conclude that usage of imipenem, meropenem, and/or ceftazidime is associated with subsequent acquisition of EDRAB in critically ill patients in ICUs.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Daniel J Morgan; Elizabeth Rogawski; Kerri A Thom; J Kristie Johnson; Eli N Perencevich; Michelle Shardell; Surbhi Leekha; Anthony D HarrisCritical care medicine 2012;40(4):1045-51.
Lisa L Maragakis; Sara E Cosgrove; Xiaoyan Song; Denny Kim; Patricia Rosenbaum; Nancy Ciesla; Arjun Srinivasan; Tracy Ross; Karen Carroll; Trish M PerlJAMA : the journal of the American Medical Association 2004;292(24):3006-11.
Kerri A Thom; William W L Hsiao; Anthony D Harris; O Colin Stine; David A Rasko; J Kristie JohnsonAmerican journal of infection control 2010;38(9):751-3.
Appears in this Publication
Author of this Publication